Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

August

Chemtos, LLC (PDF) (August 9, 2022)

Catalent Pharma Solutions, LLC (PDF) (August 9, 2022)

Botanical Sciences, LLC (PDF) (August 9, 2022)

Cerilliant Corporation (PDF) (August 9, 2022)

Cerilliant Corporation (PDF) (August 9, 2022)

Experic LLC (PDF) (August 9, 2022)

Sharp Clinical Services, LLC (PDF) (August 9, 2022)

VHG Labs, DBA LGC Standards (PDF) (August 9, 2022)

Stepan Company (PDF) (August 9, 2022)

Continuus Pharmaceutical (PDF) (August 9, 2022)

Biopharmaceutical Research Company (PDF) (August 9, 2022)

Curium US LLC (PDF) (August 9, 2022)

Bright Green Corporation (PDF) (August 9, 2022)

Chattem Chemicals (PDF) (August 9, 2022)

Michael Simental, M.D.; Decision and Order (PDF) (August 3, 2022)

Rebecca L. Adams, N.P.; Decision and Order (PDF) (August 3, 2022)

Endre Kovacs, M.D.; Decision and Order (PDF) (August 3, 2022)

30-Day Notice: Report of Mail Order Transactions (PDF) (August 1, 2022)

30-Day Notice: Reporting and Recordkeeping for Digital Certificates (PDF) (August 1, 2022)


July

Usona Institute (PDF) (July 29, 2022)

Biopharmaceutical Research Company LLC (PDF) (July 28, 2022)

AndersonBrecon Inc. (PDF) (July 28, 2022)

AMPAC Fine Chemicals Virginia, LLC (PDF) (July 28, 2022)

Akorn Operating Company, LLC DBA Akorn (PDF) (July 28, 2022)

Aspen API, Inc. (PDF) (July 28, 2022)

Withdrawal of Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I (PDF) (July 27, 2022)

Proposed Rule: Removal of Fenfluramine From Control (PDF) (July 19, 2022)

Proposed Rule: Providing Controlled Substances to Ocean Vessels, Aircraft, and Other Entities (PDF) (July 18, 2022)

Faris Abusharif, M.D.; Decision and Order (PDF) (July 18, 2022)

Xcelience (PDF) (July 15, 2022)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (July 15, 2022)

AMPAC Fine Chemicals LLC (PDF) (July 15, 2022)

Donald J. Murphy, M.D.; Decision and Order (PDF) (July 12, 2022)

Alphonsus Okoli, M.D.; Decision and Order (PDF) (July 12, 2022)

Bhanoo Sharma, M.D.; Decision and Order (PDF) (July 12, 2022)

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I (PDF) (July 6, 2022)


June

30-Day Notice: Annual Reporting Requirement for Manufacturers of Listed Chemicals (PDF) (June 30, 2022)

Cambrex Charles City (PDF) (June 30, 2022)

Adiramedica, LLC (PDF) (June 30, 2022)

American Radiolabeled Chem (PDF) (June 30, 2022)

Aurobindo Pharma USA, Inc. (PDF) (June 30, 2022)

Julie Halling, M.D.; Decision and Order (PDF) (June 27, 2022)

Kevin J. Dobi, APRN; Decision and Order (PDF) (June 27, 2022)

Jonathan Rosenfield, M.D.; Decision and Order (PDF) (June 27, 2022)

Final Rule: Placement of Serdexmethylphenidate in Schedule IV (PDF) (June 24, 2022)

Alcami Carolinas Corporation (PDF) (June 21, 2022)

Arizona Department of Corrections (PDF) (June 21, 2022)

Gary A. Matusow, D.O.; Decision and Order (PDF) (June 13, 2022)

Stepan Company (PDF) (June 7, 2022)

Pisgah Laboratories Inc. (PDF) (June 7, 2022)

Final Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (June 6, 2022)

Nusachi Labs, LLC (PDF) (June 2, 2022)

Sigma Aldrich Research Biochemicals, Inc. (PDF) (June 2, 2022)

Unither Manufacturing LLC (PDF) (June 2, 2022)

FPC Group LLC (PDF) (June 2, 2022)

Interim Final Rule: Placement of Ganaxolone in Schedule V (PDF) (June 1, 2022)

Final Rule: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I (PDF) (June 1, 2022)


May

Shah M. Mairuz Zaman, M.D.; Decision and Order (PDF) (May 31, 2022)

Omar Garcia, M.D.; Decision and Order (PDF) (May 27, 2022)

30-Day Notice: Annual Reporting Requirement for Manufacturers of Listed Chemicals (PDF) (May 26, 2022)

60-Day Notice: Report of Mail Order Transactions (PDF) (May 26, 2022)

30-Day Notice: Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 250 (PDF) (May 26, 2022)

30-Day Notice: Application for Import Quota for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 488 (PDF) (May 26, 2022)

60-Day Notice: Reporting and Recordkeeping for Digital Certificates (PDF) (May 26, 2022)

30-Day Notice: Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 189 (PDF) (May 26, 2022)

Experic, LLC (PDF) (May 25, 2022)

Almac Clinical Services Inc. (ACSI) (PDF) (May 25, 2022)

PCI Synthesis (PDF) (May 25, 2022)

Research Triangle Institute (PDF) (May 25, 2022)

Johnson Matthey Inc. (PDF) (May 25, 2022)

Wildlife Laboratories, LLC (PDF) (May 25, 2022)

Catalent Pharma Solutions, LLC (PDF) (May 25, 2022)

Scottsdale Research Institute (PDF) (May 25, 2022)

Royal Emerald Pharmaceuticals (PDF) (May 25, 2022)

United States Pharmacopeial Convention (PDF) (May 25, 2022)

Curia New York Inc. (PDF) (May 25, 2022)

Invizyne Technologies, Inc. (PDF) (May 25, 2022)

Scottsdale Research Institute (PDF) (May 23, 2022)

Fares Jeries Rabadi, M.D.; Decision and Order (PDF) (May 19, 2022)

Michael T. Harris, M.D.; Decision and Order (PDF) (May 18, 2022)

Eric David Thomas, M.D.; Denial of Application (PDF) (May 18, 2022)

60-Day Notice: Annual Reporting Requirement for Manufacturers of Listed Chemicals (PDF) (May 6, 2022)

Patheon Pharmaceuticals Inc. (PDF) (May 6, 2022)


April

SpecGx LLC (PDF) (April 28, 2022)

Lipomed (PDF) (April 28, 2022)

Royal Emerald Pharmaceuticals Research and Development (PDF) (April 28, 2022)

VHG Labs DBA LGC Standards (PDF) (April 28, 2022)

Sterling Wisconsin, LLC (PDF) (April 28, 2022)

Research Triangle Institute (PDF) (April 28, 2022)

Purisys, LLC (PDF) (April 28, 2022)

SpecGX LLC (PDF) (April 28, 2022)

Brenton D. Wynn, M.D.; Decision and Order (PDF) (April 22, 2022)

Larry S. Everhart, M.D.; Decision and Order (PDF) (April 21, 2022)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 19, 2022)

Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I (PDF) (April 12, 2022)

Proposed Rule: Exempted Prescription Products (PDF) (April 12, 2022)

Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration (PDF) (April 11, 2022)

Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 11, 2022)

Jennifer Smith, M.D.; Decision and Order (PDF) (April 11, 2022)

Gilbert Y. Kim, D.D.S.; Decision and Order (PDF) (April 11, 2022)

George Pharmacy, Inc.; Decision and Order (PDF) (April 11, 2022)

Kirk A. Hopkins, M.D.; Decision and Order (PDF) (April 11, 2022)

Kareem Hubbard, M.D.; Decision and Order (PDF) (April 11, 2022)

Noah David, P.A.; Decision and Order (PDF) (April 11, 2022)

Douglas A. Blose, M.D.; Decision and Order (PDF) (April 11, 2022)

David H. Betat, M.D.; Decision and Order (PDF) (April 11, 2022)

Craig S. Rosenblum, M.D.; Decision and Order (PDF) (April 11, 2022)

Christopher King, C.N.P.; Decision and Order (PDF) (April 11, 2022)

Crosby Pharmacy and Wellness; Decision and Order (PDF) (April 11, 2022)

Adam T. Rodman, P.A.; Decision and Order (PDF) (April 11, 2022)

Lezlie McKenzie, N.P.; Decision and Order (PDF) (April 11, 2022)

OakmontScript Limited Partnership; Decision and Order (PDF) (April 11, 2022)

Interim Final Rule: Placement of Daridorexant in Schedule IV (PDF) (April 7, 2022)

Final Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I (PDF) (April 7, 2022)

Purisys, LLC (PDF) (April 7, 2022)

Meridian Medical Technologies (PDF) (April 6, 2022)


March

Instructions to request exception to 21 CFR 1306.07(b) 3-day rule (EO-DEA248) (PDF) (March 23, 2022)

Johnson Matthey Pharmaceutical Materials, Inc. (PDF) (March 23, 2022)

Sharp Clinical Services, Inc. (PDF) (March 23, 2022)

Siemens Healthcare Diagnostics, Inc. (PDF) (March 23, 2022)

Usona Institute, Inc. (PDF) (March 23, 2022)

Patheon API Manufacturing, Inc. (PDF) (March 23, 2022)

Janssen Pharmaceuticals Inc. (PDF) (March 14, 2022)

ANI Pharmaceuticals, Inc. (PDF) (March 14, 2022)

Meridian Medical Technologies, LLC (PDF) (March 14, 2022)

Sigma Aldrich Co. LLC (PDF) (March 14, 2022)

Perkinelmer, Inc. (PDF) (March 14, 2022)

Agriculture Technology Institute, LLC (PDF) (March 14, 2022)

Peace of Mind Pharmaceuticals LLC (PDF) (March 9, 2022)

60-Day Notice; Extension: Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 189 (PDF) (March 8, 2022)

60-Day Notice; Extension: Application for Procurement Quota for Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 250 (PDF) (March 8, 2022)

60-Day Notice; Extension: Application for Import Quota for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 488 (PDF) (March 8, 2022)

S&B Pharma LLC (PDF) (March 8, 2022)

Tikun Olam Adelanto LLC (PDF) (March 8, 2022)

Caligor Coghlan Pharma Services (PDF) (March 8, 2022)

Siegfried USA, LLC (PDF) (March 8, 2022)

ANI Pharmaceuticals Inc. (PDF) (March 8, 2022)

Sterling Pharma USA, LLC (PDF) (March 2, 2022)

Janssen Pharmaceuticals, Inc. (PDF) (March 2, 2022)

Medi-Physics Inc. dba GE Healthcare (PDF) (March 2, 2022)

Emergency Disaster Relief
Search for Year Round Pharmaceutical Disposal Locations.
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility